Literature DB >> 27446456

Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression.

Shi Bin Yang1, Fanghai Han1, Jian Hai Wu1, Zhi Zhao1, Wenhua Zhan1.   

Abstract

C-X-C motif chemokine receptor type 2 (CXCR2), a key regulatory protein, has been associated with multiple roles in the progression of numerous tumors, including gastric adenocarcinoma (GA). However, the mechanism of CXCR2 in the development of tumors remains controversial and unclear. In a previous study, the expression of CXCR2 and interleukin-22 receptor 2 (IL-22BP) was observed in GA. This promoted the present study, which aimed to explore the association between the two proteins, and to further analyze their roles in GA. CXCR2 and IL-22BP protein expression was analyzed by immunohistochemistry and reverse transcription-quantitative polymerase chain reaction assays in gastric cancer (GC) tissue, additionally confirmed via western blotting and immunocytochemical analysis in the MKN-45, BGC-823 and SGC-7901 cell lines. The association between expression levels and clinicopathological characteristics was evaluated by the Mann-Whitney U and Kruskal-Wallis tests. Using Kaplan-Meier plots and Cox proportional hazard models, overall survival (OS) was analyzed. Compared with non-cancerous tissue, CXCR2 and IL-22BP were over expressed (P<0.001 and P<0.001, respectively), and were observed mainly in the cytoplasm (P=0.022 and P=0.014, respectively) in GA. The associated protein and messenger RNA levels were analyzed, and coexpression was identified. Increased expression and more positive cases of CXCR2 and IL-22BP were observed with advanced pathological tumor-node-metastasis (p-TNM) stage in GC (P<0.001 and P<0.001, respectively), as well as the presence and absence of lymph node metastasis (LNM) (P=0.003 and P=0.041, respectively) and deep or superficial muscular invasion (P=0.002 and P=0.004, respectively). In addition, an association between IL-22BP and tumor diameter was indicated (P=0.021). In a Kaplan-Meier analysis, compared with negative expression, the two proteins identified a group of patients with the shortest OS. Cox proportional hazard models revealed that the two proteins, in addition to p-TNM stage, LNM and depth of invasion, predicted a short time to OS. The coexpression of CXCR2 and IL-22BP was demonstrated in GA, which may indicate that CXCR2 is involved in more complex mechanisms and roles, and indicate a poor outcome in GA progression.

Entities:  

Keywords:  BGC-823; C-X-C motif chemokine receptor type 2; MKN-45; SGC-7901; gastric adenocarcinoma; interleukin-22 receptor 2; outcome

Year:  2016        PMID: 27446456      PMCID: PMC4950243          DOI: 10.3892/ol.2016.4790

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 2.  Chemokines and serpentines: the molecular biology of chemokine receptors.

Authors:  D J Kelvin; D F Michiel; J A Johnston; A R Lloyd; H Sprenger; J J Oppenheim; J M Wang
Journal:  J Leukoc Biol       Date:  1993-12       Impact factor: 4.962

Review 3.  The molecular biology of leukocyte chemoattractant receptors.

Authors:  P M Murphy
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 6.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

7.  Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients.

Authors:  Tommaso Zurleni; Elson Gjoni; Andrea Ballabio; Roberto Casieri; Paola Ceriani; Luca Marzoli; Francesco Zurleni
Journal:  World J Gastrointest Surg       Date:  2013-11-27

8.  Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

9.  CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct.

Authors:  S K Ahuja; J C Lee; P M Murphy
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

10.  Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid.

Authors:  J C J Martin; G Bériou; M Heslan; C Chauvin; L Utriainen; A Aumeunier; C L Scott; A Mowat; V Cerovic; S A Houston; M Leboeuf; F X Hubert; C Hémont; M Merad; S Milling; R Josien
Journal:  Mucosal Immunol       Date:  2013-05-08       Impact factor: 7.313

View more
  4 in total

1.  The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis.

Authors:  Bingbing Qiao; Wenqin Luo; Yanna Liu; Jing Wang; Chuan Liu; Zhao Liu; Sizhe Chen; Jingjing Gu; Xiaolong Qi; Tongwei Wu
Journal:  Oncotarget       Date:  2017-12-11

2.  A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis.

Authors:  Manchao Kuang; Jieyao Cheng; Chengli Zhang; Lin Feng; Xue Xu; Yajing Zhang; Ming Zu; Jianfang Cui; Hang Yu; Kaitai Zhang; Aiming Yang; Shujun Cheng
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

3.  Systematic review and meta-analysis of the prognostic value of CXCR2 in solid tumor patients.

Authors:  Yong Yang; Baoyang Luo; Yong An; Han Sun; Huihua Cai; Donglin Sun
Journal:  Oncotarget       Date:  2017-11-03

4.  C-X-C motif chemokine receptor type 2 correlates with higher disease stages and predicts worse prognosis, and its downregulation enhances chemotherapy sensitivity in triple-negative breast cancer.

Authors:  Huimin Chu; Wenhuan Li; Hai Li
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.